Trial record 1 of 1 for:
NCT04115293
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04115293 |
Recruitment Status :
Completed
First Posted : October 4, 2019
Results First Posted : January 17, 2023
Last Update Posted : May 2, 2024
|
Sponsor:
Ra Pharmaceuticals, Inc.
Information provided by (Responsible Party):
UCB Pharma ( Ra Pharmaceuticals, Inc. )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Tracking Information | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | October 2, 2019 | ||||||||||||||||
First Posted Date ICMJE | October 4, 2019 | ||||||||||||||||
Results First Submitted Date ICMJE | December 19, 2022 | ||||||||||||||||
Results First Posted Date ICMJE | January 17, 2023 | ||||||||||||||||
Last Update Posted Date | May 2, 2024 | ||||||||||||||||
Actual Study Start Date ICMJE | September 17, 2019 | ||||||||||||||||
Actual Primary Completion Date | December 30, 2021 (Final data collection date for primary outcome measure) | ||||||||||||||||
Current Primary Outcome Measures ICMJE |
Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score [ Time Frame: From Baseline to End of Treatment (Week 12) ] The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale scored 0 to 3 (0=None, 3=severe disease) point scale. The total score was the sum of all individual item scores and ranged from 0 to 24. Higher scores indicated more severe disability due to MG. A decrease from Baseline score indicated improvement.
|
||||||||||||||||
Original Primary Outcome Measures ICMJE |
Change from Baseline (CFB) in the MG-ADL Score [ Time Frame: 12 Weeks ] The MG-ADL profile provides an assessment of MG symptom severity and measures 8 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the ADL score.
|
||||||||||||||||
Change History | |||||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||||||
Original Secondary Outcome Measures ICMJE |
Change from Baseline (CFB) in the QMG Score [ Time Frame: 12 Weeks ] The QMG test is a standardized quantitative strength scoring system and measures 13 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the QMG score.
|
||||||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||
Descriptive Information | |||||||||||||||||
Brief Title ICMJE | Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis | ||||||||||||||||
Official Title ICMJE | A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis | ||||||||||||||||
Brief Summary | The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks. | ||||||||||||||||
Detailed Description | Not Provided | ||||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||||
Study Phase ICMJE | Phase 3 | ||||||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||||||||||||||
Condition ICMJE | Myasthenia Gravis, Generalized | ||||||||||||||||
Intervention ICMJE |
|
||||||||||||||||
Study Arms ICMJE |
|
||||||||||||||||
Publications * |
|
||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||
Recruitment Information | |||||||||||||||||
Recruitment Status ICMJE | Completed | ||||||||||||||||
Actual Enrollment ICMJE |
174 | ||||||||||||||||
Original Estimated Enrollment ICMJE |
130 | ||||||||||||||||
Actual Study Completion Date ICMJE | December 30, 2021 | ||||||||||||||||
Actual Primary Completion Date | December 30, 2021 (Final data collection date for primary outcome measure) | ||||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||
Sex/Gender ICMJE |
|
||||||||||||||||
Ages ICMJE | 18 Years to 74 Years (Adult, Older Adult) | ||||||||||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||
Listed Location Countries ICMJE | Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom, United States | ||||||||||||||||
Removed Location Countries | |||||||||||||||||
Administrative Information | |||||||||||||||||
NCT Number ICMJE | NCT04115293 | ||||||||||||||||
Other Study ID Numbers ICMJE | RA101495-02.301 | ||||||||||||||||
Has Data Monitoring Committee | Not Provided | ||||||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||||||
Current Responsible Party | UCB Pharma ( Ra Pharmaceuticals, Inc. ) | ||||||||||||||||
Original Responsible Party | Ra Pharmaceuticals | ||||||||||||||||
Current Study Sponsor ICMJE | Ra Pharmaceuticals, Inc. | ||||||||||||||||
Original Study Sponsor ICMJE | Ra Pharmaceuticals | ||||||||||||||||
Collaborators ICMJE | Not Provided | ||||||||||||||||
Investigators ICMJE |
|
||||||||||||||||
PRS Account | UCB Pharma | ||||||||||||||||
Verification Date | April 2024 | ||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |